Ozmosi | Prednisone Drug Profile

Product Description

Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30521230/)

Mechanisms of Action: GR Agonist, Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Prednisone

Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 66

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
2024-516905-22-00	2024-516905-22-00	P3	Active, not recruiting	Multiple Myeloma	2031-12-31		2025-05-02	Treatments
NCT06072131	CRESCENDO	P3	Recruiting	T-Cell Peripheral Lymphoma	2030-07-01	18%	2024-11-27
NCT07097363	RG1125011	P2	Recruiting	T-Cell Lymphoma\|Lymphoma, Non-Hodgkin\|Diffuse Large B-Cell Lymphoma\|Burkitt Lymphoma	2030-05-31	12%	2025-12-18	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT07412470	FREXERA	P3	Not yet recruiting	Kidney Transplant	2029-08-15	33%	2026-02-18
NCT05848765	REFRACT	P2	Recruiting	Follicular Lymphoma	2029-05-31	78%	2024-11-27
NCT04175431	RG1004972	P2	Recruiting	Adenocarcinoma\|Prostate Cancer	2028-07-01	12%	2025-12-19	Primary Completion Date\|Primary Endpoints\|Study Completion Date
NCT06738368	RG1124788	P2	Recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|T-Cell Leukemia\|Acute Lymphoid Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Burkitt Lymphoma	2028-01-31	12%	2026-01-31
NCT03952637	19-HG-0101	P2	Recruiting	Gangliosidoses\|GM1 Gangliosidosis\|Gangliosidosis, GM1	2028-01-01	12%	2025-08-27	Primary Endpoints
NCT06585774	INCA34176-357	P3	Recruiting	Graft vs Host Disease\|Bronchiolitis Obliterans	2027-09-28	35%	2024-12-06	Primary Endpoints\|Treatments\|Trial Status
NCT06954805	AAAV2404	P2	Recruiting	Lymphoma, B-Cell\|Lymphoproliferative Disorders	2027-04-14		2025-05-03	Primary Endpoints\|Treatments
NCT06624670	U1111-1306-8055	P3	Recruiting	Pyoderma Gangrenosum	2027-04-12	24%	2025-09-20	Primary Completion Date\|Primary Endpoints\|Study Completion Date
jRCT2033240447	jRCT2033240447	P2	Recruiting	Cardiomyopathy, Dilated\|Heart Failure	2027-03-31
NCT03595917	NCT03595917	P1	Recruiting	Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Blast Crisis\|Acute Lymphoid Leukemia\|Chronic Lymphoid Leukemia\|B-Cell Leukemia\|Lymphoma, B-Cell\|Burkitt Lymphoma\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2026-11-01	12%	2025-11-05	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT03117751	TOT17	P3	Active, not recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2026-09-30	10%	2024-11-27	Primary Endpoints\|Treatments
NCT02684708	EuroNet-PHL-C2	P3	Active, not recruiting	Hodgkin Lymphoma	2026-09-30		2021-05-14	Primary Endpoints\|Treatments\|Trial Status
2024-511383-88-00	SC-3C2A	P3	Active, not recruiting	Asthma, Allergic\|Rhinitis, Allergic\|Conjunctivitis, Allergic	2026-09-30		2025-05-02	Treatments
NCT04980222	GO43075	P2	Active, not recruiting	Lymphoma	2026-09-30	12%	2025-11-19	Primary Completion Date\|Primary Endpoints\|Treatments
2023-508614-41-00	2023-0038	P2	Recruiting	Allogeneic Stem Cell Transplant	2026-09-01		2025-05-02	Treatments
2022-000712-59	SEM-CORTICO (Severe Erythema Multiforme - CORTICO)	P3	Active, not recruiting	Erythema Multiforme	2026-08-07
NCT04812366	GUNS	P2	Recruiting	Prostate Cancer	2026-04-01	12%	2022-02-08	Primary Endpoints\|Treatments
NCT06172361	ITTGPMR	P3	Recruiting	Polymyalgia Rheumatica\|Giant Cell Arteritis	2025-09-30		2024-07-30	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT05267600	BALLAD	P3	Completed	Pemphigoid, Bullous	2024-09-13	57%	2024-10-16	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Trial Status
NCT02496585	NCT02496585	P2	Completed	Radiation Pneumonitis\|Lung Cancer	2024-04-12	24%	2025-08-27	Primary Endpoints\|Treatments
NCT05288166	CYCLONE 3	P3	Active, not recruiting	Drug Hypersensitivity\|Prostate Cancer	2024-02-15	17%	2025-06-28
2017-000390-37	MASTER-ANCA	P3	Active, not recruiting	Kidney Diseases	2023-12-01		2022-03-13	Treatments

Recent News Events

Date	Type	Title
02/16/2026	News Article	Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
02/12/2026	News Article	Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
02/10/2026	News Article	Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
01/29/2026	News Article	AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Prednisone